Navigation Links
Jennerex Reports Positive Mechanistic Proof-of-Concept Clinical Trial Results Using JX-594 to Treat Metastatic Melanoma
Date:8/2/2011

ion: 1) the lysis of cancer cells through viral replication, 2) the reduction of the blood supply to tumors through vascular targeting and destruction, and 3) the stimulation of the body's immune response against cancer cells, i.e., active immunotherapy. Phase 1 and Phase 2 clinical trials in multiple cancer types to date have shown that JX-594, delivered either directly into tumors or systemically, induces tumor shrinkage and/or necrosis and is well-tolerated by patients (over 100 treated to date). Objective tumor responses have been demonstrated in a variety of cancers including liver, colon, kidney, lung and melanoma. JX-594 has a favorable safety profile with predictable and generally mild side effects that typically include flu-like symptoms that resolve in 48 to 72 hours.

The poxvirus strain backbone of JX-594 has been used safely in millions of people as part of a worldwide vaccination program. This strain naturally targets cancer cells due to common genetic defects in cancer cells. JX-594 was engineered to enhance this natural safety and cancer-selectivity by deleting its thymidine kinase (TK) gene, thus making it dependent on the cellular TK expressed at persistently high levels in cancer cells. To enhance product efficacy, JX-594 is also engineered to express the GM-CSF protein. GM-CSF complements the cancer cell lysis work of the product candidate, leading to a cascade of events resulting in tumor necrosis, tumor vasculature shutdown and an anti-tumoral immune attack.

About Jennerex's Partners for JX-594

Transgene (NYSE Euronext Paris: FR0005175080), a bio-pharmaceutical company specialized in the development of immunotherapeutic products, holds an exclusive license to develop and commercialize JX-594 in Europe and neighboring countries. Green Cross Corporation, a leading company in the development, manufacturing, and commercialization of viral vaccines and other biological products, holds an exclusive license to develop and c
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Jennerex and Partners Present Positive JX-594 Randomized Phase 2 Clinical Data Showing Promising Survival Benefit in Patients with Advanced Liver Cancer
2. Jennerex to Present JX-594 Liver Cancer Clinical Data at American Society of Gene and Cell Therapy Meeting
3. Jennerex Appoints James M. Burke, M.D. Vice President, Clinical Research
4. Jennerex and Transgene Enter Into an Exclusive Partnership for the Development and Commercialization of JX-594 for the Treatment of Cancers
5. Jennerex Completes Fully Subscribed Private Placement for Aggregate Gross Proceeds of $8.6 Million
6. Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
7. Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
8. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
9. Jennerex Closes $5 Million First Tranche of Series C Financing
10. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
11. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 23, 2013 On April 19th the ... supermarkets to search for the growing antibiotic resistant bacteria ... from a year long study were released late last ... specifically meats, over previous years. For those suffering from ... of antibiotic resistant bacteria in food, may eventually help ...
(Date:5/23/2013)... May 23, 2013 The New Jersey ... industries, Black Data Processing Associates (BDPA), is hosting its ... 8, 2013. This all-day event will encourage students and ... the ins and outs from many of the industries’ ... at the New Jersey Institute of Technology, the event ...
(Date:5/23/2013)... Toronto, Canada (PRWEB) May 23, 2013 ... subjects, it is critical to adhere to principles ... protection (HSP). , Esteemed speaker Dr. Jeremy Lim, ... the audience: , ,     Understand the ... Clinical Practice (GCP) and additional regulations for the ...
(Date:5/23/2013)... May 23, 2013 African ... tracing for people of African descent, today announced ... offering. For people of all races, myDNAmix determines ... five distinct populations: Indigenous Americas (Native American), East ... Subcontinent. , Originally launched in late ...
Breaking Biology Technology:Acne Cream, Probiotic Action Shares News on How Some Food may Breed Acne Causing Bacteria 2Black Data Processing Associates (BDPA) New Jersey Hosts 10th Annual Families in Technology Day June 8, 2013 2Adhering to Good Clinical Practice, New Webinar Hosted by Xtalks 2AfricanAncestry.com Rolls Out Improved MyDNAMix Admixture Test for People of all Races; Enhancements Increase Accuracy in Estimation of Ancestral Makeup 2AfricanAncestry.com Rolls Out Improved MyDNAMix Admixture Test for People of all Races; Enhancements Increase Accuracy in Estimation of Ancestral Makeup 3
... Genmab,s Partner, Roche has Initiated a Phase II study of R1507 ... for ... A/S,(OMX: GEN) announced today that its partner, Roche has initiated a ... refractory,sarcoma. The R1507 antibody was created by Genmab under the company,s,agreement ...
... December 20 ExonHit Therapeutics, a,drug and diagnostic discovery ... to initiate a Phase 2 clinical trial of its,therapeutic ... is a compound, with a novel mechanism of action, ... This will be the first Phase 2 clinical trial ...
... Walk Adds Houston, TX to 2008 Lineup; Looks to Build Upon 2007 ... Record-Breaking ... access to care and finding a cure for breast cancer, the Avon,Foundation ... time in Avon Walk history, the series will expand into a,ninth market ...
Cached Biology Technology:Genmab A/S - R1507 Antibody to Enter Phase II Study to Treat Sarcoma 2ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimer's Disease 2ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimer's Disease 3ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimer's Disease 4Avon Foundation Announces 2008 Avon Walk for Breast Cancer Schedule 2Avon Foundation Announces 2008 Avon Walk for Breast Cancer Schedule 3
(Date:5/22/2013)... environmental and human health effects from disposal of ... led scientists to recommend stronger government policies to ... battery materials. That,s the conclusion of a new ... & Technology . , Oladele A. Ogunseitan and ... mainstays for powering everything from smart phones to ...
(Date:5/22/2013)... the biodiversity of pollinating insects and wild plants have ... , Researchers led by the University of Leeds and ... evidence of dramatic reductions in the diversity of species ... and 1980s. , But the picture brightened markedly after ... losses among bees, hoverflies and wild plants. ...
(Date:5/21/2013)... A new analysis shows that the nation,s land ... enough algae to produce up to 25 billion gallons ... one-twelfth of the country,s yearly needs. , The findings ... that would be needed to grow significant amounts of ... were published in the May 7 issue of ...
Breaking Biology News(10 mins):Encouraging signs for bee biodiversity 2Encouraging signs for bee biodiversity 3Going green: Nation equipped to grow serious amounts of pond scum for fuel 2Going green: Nation equipped to grow serious amounts of pond scum for fuel 3Going green: Nation equipped to grow serious amounts of pond scum for fuel 4
... much or more by environmental change than tropical rain ... who serves as director of the Oklahoma Biological Survey. ... necessarily think of the common species in freshwater systems, ... need to be concerned about these declines, because these ...
... before form, members of the Perissodinus genus of ... distinct feeding advantage. Research published in the open access journal ... cichlids, develop mouths directed either to the left or the ... of their prey. A research team from Syracuse ...
... over the long-term, according to new research published Jan. 25, ... shows for the first time that some virgin births can ... Field Museum scientist working with numerous colleagues has confirmed the ... offspring that survived. Two daughters of the white-spotted bamboo shark ...
Cached Biology News:Environmental change impacts Oklahoma rivers 2Lopsided fish show that symmetry is only skin deep 2Study of shark virgin birth shows offspring can survive long term 2
... FROM MOISTURE. AVOID FREEZE/THAW CYCLES. This kit ... in vitro by DNA affinity-mediated capture ... detection. In this assay, mono- and oligonucleosomes ... Anti-Histone 3 (H3) biotin-labeled antibody then binds ...
... cell lines in combination with the ... parameters. Nucleofector Kits are only functional ... Different cell lines can be transfected ... and viabilities are given in brackets ...
... solution or in a gel piece, we can ... be digested to produce a mixture of peptides. ... determined by MALDI-TOF, and the amino acid sequences ... will be determined by MALDI-TOF/TOF. The masses and ...
For cleavage of 6xHis tags from proteins containing a Factor Xa Protease recognition site Efficient 6xHis tag cleavage (greater than 90%), ...
Biology Products: